tat-d1ri

Tat-D1Ri is a **cell-permeable interfering peptide** designed to disrupt the interaction between the dopamine D1 receptor (D1R) and the GluN1 subunit of the N-methyl-D-aspartate receptor (NMDAR) in the brain. It contains a Tat cell membrane transduction domain (sequence YGRKKRRQRRR) that enables cell entry and a core region derived from the D1R C-terminal motif responsible for binding GluN1. Tat-D1Ri inhibits the protein–protein interaction between D1R and GluN1, resulting in downregulation of aberrant signaling associated with levodopa-induced dyskinesia (LID) in Parkinson’s disease models. In preclinical research, intrastriatal administration of Tat-D1Ri reduced dyskinetic behaviors, decreased phosphorylation of DARPP-32 at Thr34, altered membrane expression of GluN1, and increased D1R membrane localization. The primary proposed therapeutic indication is **dyskinesia in Parkinson’s disease** related to chronic L-dopa therapy[1].

Other names

tat-d1ritat-d-1ritat-d 1ri